Myrtle Potter has served as a member of Guardant Health’s board of directors since October 2021. Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma, Inc., the parent company of five biotechnology subsidiaries, since December 2019. Prior to this, she served as Vant Operating Chair at Roivant Sciences, Inc. from July 2018 to December 2019. In that role, she oversaw nine biopharmaceutical companies with over thirty investigational drugs in eleven therapeutic areas. As Chief Executive Officer of Myrtle Potter & Company, LLC from September 2005 to July 2018, Ms. Potter and her hand-picked team of experts led major strategic efforts and the preparation for multiple product launches for numerous biopharmaceutical companies. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to joining Genentech, she held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb, and Vice President at Merck & Co. While at Merck, she started the company Astra Merck Incorporated which later, through a series of transactions, became a part of AstraZeneca PLC. Ms. Potter currently serves on the board of Liberty Mutual Insurance Group, Opentrons Labworks, Inc. and the Board of Trustees of The University of Chicago, and has previously served on the boards of Amazon.com, Inc., Axsome Therapeutics, Inc., Express Scripts Holding Company, and Medco Health Solutions, Inc. Ms. Potter holds a Bachelor of Arts Degree from The University of Chicago.
- Member of the Audit Committee
- Member of the Compensation Committee